Pfiz­er prunes three drugs from its pipeline; Astel­las in-li­cens­es ear drug

• Pfiz­er’s lat­est pipeline up­date comes with a no­tice of three mid­night pro­gram ex­e­cu­tions. The phar­ma gi­ant has pruned three drugs from its sub­stan­tial pipeline, ac­cord­ing to the up­date. The most ad­vanced is a Phase II di­a­betes pro­gram for PF-06291874; fol­lowed by the ear­ly stage car­dio drug PF-06815345 (hy­per­lipi­demia) as well as the neu­ro drug PF-06412562, al­so in Phase I. None of these were high pro­file projects, none of the ter­mi­na­tions were ex­plained.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER